CU24387B1 - Inhibidores de bmi-1 de pirimidina inversa sustituida - Google Patents

Inhibidores de bmi-1 de pirimidina inversa sustituida

Info

Publication number
CU24387B1
CU24387B1 CU2015000053A CU20150053A CU24387B1 CU 24387 B1 CU24387 B1 CU 24387B1 CU 2015000053 A CU2015000053 A CU 2015000053A CU 20150053 A CU20150053 A CU 20150053A CU 24387 B1 CU24387 B1 CU 24387B1
Authority
CU
Cuba
Prior art keywords
bmi
replaced
inhibitors
pyrimidine
reduce
Prior art date
Application number
CU2015000053A
Other languages
English (en)
Other versions
CU20150053A7 (es
Inventor
Ramil Baiazitov
Liangxian Cao
Thomas W Davis
Wu Du
Chang-Sun Lee
Ronnggang Liu
Young-Choon Moon
Steven D Paget
Hongyu Ren
Nadiya Sydorenko
Richard Gerald Wilde
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CU20150053A7 publication Critical patent/CU20150053A7/es
Publication of CU24387B1 publication Critical patent/CU24387B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

<p>Compuestos inversos de pirimidina sustituidos con amina de fórmula I</p> <p>(ESPACIO PARA LA FÓRMULA)</p> <p> y formas de la misma que inhiben la función y reducen el nivel de la proteína del sitio de integración 1 (Bmi-1) del virus de la leucemia de Moloney específico de células B para su uso para inhibir la función de Bmi-1 y reducir el nivel de Bmi-1 para el tratamiento de un cáncer mediado por Bmi-1 se describen en el presente documento.</p>
CU2015000053A 2012-11-21 2013-11-21 Inhibidores de bmi-1 de pirimidina inversa sustituida CU24387B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Publications (2)

Publication Number Publication Date
CU20150053A7 CU20150053A7 (es) 2015-11-27
CU24387B1 true CU24387B1 (es) 2019-03-04

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2015000053A CU24387B1 (es) 2012-11-21 2013-11-21 Inhibidores de bmi-1 de pirimidina inversa sustituida

Country Status (32)

Country Link
US (3) US10428050B2 (es)
EP (1) EP2922828B1 (es)
JP (3) JP6412503B2 (es)
KR (4) KR20220143164A (es)
CN (2) CN104918919A (es)
AR (1) AR093579A1 (es)
AU (1) AU2013348009C1 (es)
BR (1) BR112015011760B1 (es)
CA (1) CA2892045C (es)
CL (1) CL2015001377A1 (es)
CR (1) CR20150294A (es)
CU (1) CU24387B1 (es)
DK (1) DK2922828T3 (es)
EA (2) EA031405B1 (es)
EC (1) ECSP15019948A (es)
ES (1) ES2821529T3 (es)
HK (1) HK1215032A1 (es)
IL (2) IL238871B (es)
MA (1) MA38208B1 (es)
MX (2) MX2015006469A (es)
NI (1) NI201500072A (es)
NZ (2) NZ746607A (es)
PE (1) PE20151413A1 (es)
PH (1) PH12015501130A1 (es)
PL (1) PL2922828T3 (es)
PT (1) PT2922828T (es)
SA (1) SA517381847B1 (es)
SG (2) SG10201600149VA (es)
TW (1) TWI623531B (es)
UA (1) UA118094C2 (es)
WO (1) WO2014081906A2 (es)
ZA (1) ZA201503642B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2922828T3 (pl) 2012-11-21 2020-12-28 Ptc Therapeutics, Inc. Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) * 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
TWI692477B (zh) 2013-08-30 2020-05-01 美商Ｐｔｃ治療公司 經取代嘧啶ｂｍｉ-１抑制劑
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CA3010615C (en) * 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CA3053245A1 (en) 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
AU2019340402A1 (en) 2018-08-17 2021-03-25 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
US20220096473A1 (en) * 2019-01-15 2022-03-31 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
AU2020227748A1 (en) * 2019-02-28 2021-09-16 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof
BR112021018770A2 (pt) 2019-03-22 2022-02-15 Cognoa Inc Métodos e dispositivos de terapia digital personalizada
JP2022519930A (ja) * 2019-03-27 2022-03-25 ピーティーシー セラピューティクス， インコーポレイテッド 肉腫を治療する方法に有用な組み合わせ
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) 1973-09-20 1977-11-30 Delalande Sa
ES2201112T3 (es) 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
IN188411B (es) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
EP1330452B1 (en) 2000-09-20 2008-11-26 Ortho-McNeil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1377573B1 (en) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
IL156784A0 (en) 2001-02-20 2004-02-08 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
ES2271283T3 (es) 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
IL165262A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Kinase inhibitors
CN100343237C (zh) 2002-06-28 2007-10-17 日本新药株式会社 酰胺衍生物及医药品
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US7060850B2 (en) * 2002-07-11 2006-06-13 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004035588A1 (en) 2002-10-15 2004-04-29 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
GB2424882B (en) 2004-01-12 2008-08-06 Cytopia Res Pty Ltd Selective kinase inhibitors
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
ES2398712T3 (es) * 2004-03-30 2013-03-21 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de JAK y otras proteínas quinasas
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
CA2601257A1 (en) 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
CA2665398A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
BRPI0717773A2 (pt) * 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
TW200846344A (en) 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MX2010005300A (es) 2007-11-16 2010-06-25 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
JP2011506303A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー ピラゾール誘導体およびサイクリン依存性キナーゼの阻害剤としてのその使用
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
ES2605815T3 (es) 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
EP2328890B1 (en) 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
US8618099B2 (en) 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
TW201028399A (en) * 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
KR20110120286A (ko) 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체
CN102448958B (zh) 2009-03-27 2015-10-21 维特Dc公司 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途
ES2453097T3 (es) 2009-05-27 2014-04-04 Abbvie Inc. Inhibidores de pirimidina de actividad quinasa
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
KR101702609B1 (ko) * 2009-06-17 2017-02-03 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2606126B1 (en) * 2010-08-19 2016-05-18 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
CN103221408A (zh) 2010-09-13 2013-07-24 诺瓦提斯公司 三嗪-*二唑类化合物
US20140088056A1 (en) 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2649065A1 (en) 2010-12-09 2013-10-16 Amgen Inc. Bicyclic compounds as pim inhibitors
US9850227B2 (en) 2011-02-25 2017-12-26 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
US9199962B2 (en) 2011-07-07 2015-12-01 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PL2922828T3 (pl) * 2012-11-21 2020-12-28 Ptc Therapeutics, Inc. Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
NZ746607A (en) 2019-11-29
CA2892045C (en) 2022-05-31
CU20150053A7 (es) 2015-11-27
CA2892045A1 (en) 2014-05-30
IL238871A0 (en) 2015-07-30
ECSP15019948A (es) 2016-01-29
NI201500072A (es) 2016-01-18
SG10201600149VA (en) 2016-02-26
KR102455889B1 (ko) 2022-10-17
AU2013348009B2 (en) 2018-05-17
EP2922828B1 (en) 2020-07-08
MX2021009892A (es) 2021-09-14
EA201590992A1 (ru) 2015-11-30
KR20220143164A (ko) 2022-10-24
EA201890142A1 (ru) 2018-06-29
KR20220016305A (ko) 2022-02-08
US20150315182A1 (en) 2015-11-05
JP6918898B2 (ja) 2021-08-11
ZA201503642B (en) 2020-10-28
PE20151413A1 (es) 2015-10-23
JP2016504290A (ja) 2016-02-12
KR102275676B1 (ko) 2021-07-12
JP2020055815A (ja) 2020-04-09
US20200024260A1 (en) 2020-01-23
AR093579A1 (es) 2015-06-10
TWI623531B (zh) 2018-05-11
MA38208B1 (fr) 2021-12-31
ES2821529T3 (es) 2021-04-26
IL238871B (en) 2019-03-31
NZ708909A (en) 2019-11-29
EA031405B1 (ru) 2018-12-28
JP2019031509A (ja) 2019-02-28
US20220064150A1 (en) 2022-03-03
CN111423417B (zh) 2022-11-15
PL2922828T3 (pl) 2020-12-28
JP6412503B2 (ja) 2018-10-24
KR20150086345A (ko) 2015-07-27
HK1215032A1 (zh) 2016-08-12
AU2013348009A1 (en) 2015-06-04
MX2015006469A (es) 2015-10-29
EP2922828A4 (en) 2016-07-27
CN104918919A (zh) 2015-09-16
PT2922828T (pt) 2020-10-12
UA118094C2 (uk) 2018-11-26
CL2015001377A1 (es) 2016-02-19
KR102356487B1 (ko) 2022-02-08
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
CN111423417A (zh) 2020-07-17
KR20210088740A (ko) 2021-07-14
JP6617186B2 (ja) 2019-12-11
PH12015501130A1 (en) 2015-08-03
SG11201503982XA (en) 2015-06-29
US10428050B2 (en) 2019-10-01
US11180483B2 (en) 2021-11-23
BR112015011760B1 (pt) 2022-12-06
DK2922828T3 (da) 2020-08-31
BR112015011760A2 (pt) 2017-07-11
AU2013348009C1 (en) 2019-08-08
WO2014081906A3 (en) 2014-07-17
TW201427972A (zh) 2014-07-16
EP2922828A2 (en) 2015-09-30
IL265253A (en) 2019-05-30
CR20150294A (es) 2015-08-20
EA035349B1 (ru) 2020-05-29

Similar Documents

Publication Publication Date Title
CU24387B1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CL2022001671A1 (es) Inhibidores de sos1
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
SV2016005149A (es) Polimorfo de los inhibidores de la syk
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CO2018006164A2 (es) Compuestos útiles como inhibidores de cinasa
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
MX2016002642A (es) Inhibidores de la bmi-1 de pirimidina sustituida.
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina